1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Jenburkt Pharmaceuticals Limited

Jenburkt Pharmaceuticals Limited

JENBURPH.BO
Jenburkt Pharmaceuticals LimitedIN flagBombay Stock Exchange
1,097.00
INR
-17.90
- -
4.84BMarket Cap
Jenburkt Pharmaceuticals Limited
JENBURPH.BO
(Bombay Stock Exchange)

Recent

price

1,097.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
122.42
128.66
149.15
163.95
183.28
201.29
222.2
249.87
267.24
259.06
237.22
269.6
298.18
320.92
343.74
- -
350.52
Revenue per Share
12.94
12.89
13.37
16.15
20.75
23.18
29.05
37.5
43.14
32.4
35.96
48.58
53.9
58.86
72.65
- -
73.5
Basic EPS, GAAP
7.26
5.77
4.62
22.52
16.98
11.37
20.6
34.28
23.06
22.8
39.9
13.55
32.74
12.62
18.56
- -
- -
Free Cash Flow per Basic Share
3.5
3.5
4.2
5.1
6.3
7.2
-0.4
14.41
3.18
18.7
- -
10.2
12.05
14.32
15.36
- -
- -
Dividend per Share
28.36
35.99
43.14
51.54
64.72
79.24
108.3
126.08
161.25
172.13
208.09
246.47
257.4
313.9
377.87
- -
- -
Book Value per Share
31.08
40.06
48.59
58.69
71.87
87.23
116.81
133.22
168.44
172.49
213.5
255.1
267.65
327.54
388.73
- -
- -
Tangible Book Value per Share
5
5
5
5
5
5
5
5
5
5
5
5
5
4
4
- -
4
Basic Weighted Avg Shares
569
598
693
762
852
936
1,033
1,147
1,226
1,189
1,089
1,237
1,361
1,416
1,517
1,687
1,547
Sales/Revenue/Turnover
16.19
13.8
12.44
13.07
14.78
15.46
17.39
19.62
19.26
14.67
16.36
20.49
20.65
21.73
24.83
24.08
24
Operating Margin (%)
10
12
15
16
27
20
18
15
14
23
20
19
23
23
27
31
29
Depreciation Expense
60
60
62
75
96
108
135
172
198
149
165
223
246
260
321
347
324
Net Income, GAAP
33.82
29.64
29.56
27.33
32.71
35.95
34.04
31.88
25.67
29.65
23.75
25.35
25.13
26.15
27.02
25.33
26.37
Effective Tax Rate (%)
10.57
10.02
8.96
9.85
11.32
11.52
13.08
15.01
16.14
12.51
15.16
18.02
18.07
18.34
21.14
20.59
20.97
Profit Margin (%)
122
129
169
169
250
309
456
529
671
697
620
546
653
933
377
719
- -
Working Capital
1
1
- -
- -
- -
2
2
2
- -
14
9
5
- -
- -
15
18
- -
LT Debt
146
187
227
273
334
407
544
613
775
800
985
1,174
1,224
1,449
1,718
1,970
- -
Total Equity
37.9
30.77
25.2
25.61
24.43
21.48
22.07
24.99
23.98
14.4
14.36
16.64
16.93
16.9
17.29
16.21
- -
Return on Invested Capital (%)
42.77
34.86
28.47
30.63
31.51
27.84
27.75
30.38
28.74
18.37
18.22
20.47
20.67
20.19
20.95
39.52
563.91
Return on Capital (%)
52.9
40.08
33.79
34.11
35.7
32.21
30.98
31.81
30.03
19.44
18.91
21.38
21.34
20.29
21
40.59
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
24
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
15
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
4
- -
Market Capitalization
5,361
4,465
6,055

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
565
- -
Cash, Cash Equivalents & STI
- -
231
- -
Accounts Receivable, Net
- -
207
- -
Inventories
- -
89
- -
Total Current Liabilities
- -
188
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
24
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.42%
15.03%
14.71%
Free Cash Flow
30.15%
23.01%
56.3%
Net Income, GAAP
13.67%
16.56%
8.34%
Sales/Revenue/Turnover
6.29%
9.21%
11.24%
Total Cash Common Dividend
- -
2.27%
17.09%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
292
383
357
385
1,416
2025
325
412
369
410
1,517
2026
355
430
446
- -
1,687

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12.17
16.59
12.25
- -
58.86
2025
16.8
21.75
14.75
19.34
72.65
2026
17.66
13.44
24.58
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
14.32
2025
- -
- -
- -
- -
15.36
2026
- -
- -
- -
- -
- -
Similar Companies
Gedeon Richter PLC (RGEDF)
TG Therapeutics, Inc. (0VGI.L)
Upper Street Marketing Inc. (UPPR)
Neurizon Therapeutics Limited (NUZ.AX)
Medican Enterprises, Inc. (MDCN)
Redcare Pharmacy N.V. (SHPPF)
Business
Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations and healthcare products in India and internationally across 13 countries. Founded in 1985 and headquartered in Mumbai, India, the company offers a broad portfolio of prescription and over-the-counter drugs spanning therapeutic areas including anti-fungals, anti-ulcerants and antacids, aphrodisiacs, anti-malarials, anthelmintics, anti-diabetics, pain management, analgesics and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain treatments, anti-arthritics, anti-infectives, cough and cold remedies, dermatological products, and consumer healthcare items; key brands include Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega, Nervijen P, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zixa, and Zydol Suspension. The company operates a WHO-GMP approved manufacturing plant in Sihor, Gujarat, supported by an R&D unit approved by the Ministry of Science and Technology, Government of India, and serves government institutions, hospitals, pharmacies, and over 100,000 doctors through more than 1,000 stockists and 400,000 pharmacies globally. In recent developments, Jenburkt Pharmaceuticals reports consistent revenue and profit growth, with net profit rising 5.83% to Rs 10.16 crore and sales up 10.53% to Rs 45.56 crore in the quarter ended September 2025; the company also launched a new over-the-counter division, Jenburkt Wellness, in fiscal year 2021-22 to expand into physical wellness products, increased its final dividend to Rs 18 per share in 2025, and maintains steady institutional holdings while adopting technologies like SAP S4 HANA for operational efficiency.